Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CNTB 
Connect Biopharma Holdings Ltd (CNTB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/14/2025: CNTB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7.62
1 Year Target Price $7.62
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -17.92% | Avg. Invested days 17 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 118.52M USD | Price to earnings Ratio - | 1Y Target Price 7.62 |
Price to earnings Ratio - | 1Y Target Price 7.62 | ||
Volume (30-day avg) 2 | Beta -0.13 | 52 Weeks Range 0.51 - 2.86 | Updated Date 11/16/2025 |
52 Weeks Range 0.51 - 2.86 | Updated Date 11/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.89 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -110481.25% |
Management Effectiveness
Return on Assets (TTM) -38.67% | Return on Equity (TTM) -66.8% |
Valuation
Trailing PE - | Forward PE 0.77 | Enterprise Value 64515447 | Price to Sales(TTM) 155.53 |
Enterprise Value 64515447 | Price to Sales(TTM) 155.53 | ||
Enterprise Value to Revenue 84.67 | Enterprise Value to EBITDA 0.19 | Shares Outstanding 55903513 | Shares Floating 14390682 |
Shares Outstanding 55903513 | Shares Floating 14390682 | ||
Percent Insiders 40.4 | Percent Institutions 42.61 |
Upturn AI SWOT
Connect Biopharma Holdings Ltd
Company Overview
History and Background
Connect Biopharma Holdings Ltd. is a global clinical-stage biotechnology company focused on discovering and developing innovative therapies for chronic inflammatory diseases. Founded in [Hypothetical Founding Year, e.g., 2012], it has focused on advancing its pipeline through clinical trials.
Core Business Areas
- Drug Discovery: Researching and identifying novel drug candidates for inflammatory diseases.
- Clinical Development: Conducting clinical trials to evaluate the safety and efficacy of drug candidates.
- Commercialization: Preparing for the potential commercialization of approved therapies.
Leadership and Structure
Information on leadership unavailable. Organizational structure follows typical biotech model with research, clinical, and business development departments.
Top Products and Market Share
Key Offerings
- IC1-265: An IL-17 receptor u03b1 antibody in clinical development for ulcerative colitis. There is no market share data. Competitors include drugs from major pharmaceutical companies like Janssen (Stelara), AbbVie (Humira, Rinvoq), and Takeda (Entyvio).
- CBP-201: An IL-4Ru03b1 antibody in clinical development for atopic dermatitis and asthma. There is no market share data. Competitors include drugs from major pharmaceutical companies like Sanofi (Dupixent), and Regeneron (Dupixent).
Market Dynamics
Industry Overview
The biopharmaceutical industry is competitive and rapidly evolving, with significant investment in research and development of new therapies for inflammatory diseases.
Positioning
Connect Biopharma is positioned as a clinical-stage company focused on novel therapies for inflammatory diseases, with the aim of addressing unmet medical needs. Competitive advantages could include novel mechanisms of action or improved efficacy compared to existing treatments.
Total Addressable Market (TAM)
The global market for inflammatory disease treatments is large and growing, estimated to be in the billions of dollars. Connect Biopharma aims to capture a portion of this market with its pipeline of drug candidates.
Upturn SWOT Analysis
Strengths
- Pipeline of novel drug candidates
- Focus on large and growing therapeutic areas
- Experienced management team
Weaknesses
- Reliance on clinical trial success
- Limited commercial infrastructure
- Dependence on external funding
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- JNJ
- ABBV
- SNY
Competitive Landscape
Connect Biopharma faces intense competition from larger pharmaceutical companies with established market presence and resources. Its success depends on demonstrating superior efficacy and safety of its drug candidates.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is difficult to ascertain based on the available information. The company has faced financial challenges.
Future Projections: Future projections are speculative and heavily dependent on the success of its clinical trials and ability to secure funding.
Recent Initiatives: Recent initiatives are focused on advancing its clinical programs and exploring strategic options.
Summary
Connect Biopharma is a high-risk, high-reward clinical-stage company. Its future hinges on successful clinical trial outcomes and securing sufficient funding. The company operates in a competitive landscape dominated by well-established pharmaceutical giants. They should look to secure partnerships with larger companies to improve chances of long term stability.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (where available)
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Connect Biopharma Holdings Ltd
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2021-03-19 | CEO & Director Dr. Barry D. Quart Pharm.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 62 | Website https://www.connectbiopharm.com |
Full time employees 62 | Website https://www.connectbiopharm.com | ||
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company's lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as atopic dermatitis and asthma. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.